Obi Greenman
Chief Executive Officer bij CERUS CORPORATION
Vermogen: 6 M $ op 31-03-2024
Profiel
William Mariner Greenman is currently the President, Chief Executive Officer & Director at Cerus Corp.
He previously served as an Independent Director at Aduro BioTech, Inc. and Chinook Therapeutics, Inc. He also held the position of Senior Vice President-Biotech Division at Baxter International, Inc. Mr. Greenman obtained his undergraduate degree from Stanford University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CERUS CORPORATION
1.75% | 14-03-2024 | 3 181 281 ( 1.75% ) | 6 M $ | 31-03-2024 |
Actieve functies van Obi Greenman
| Bedrijven | Functie | Begin |
|---|---|---|
| CERUS CORPORATION | Chief Executive Officer | 21-04-2011 |
Eerdere bekende functies van Obi Greenman
| Bedrijven | Functie | Einde |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 11-08-2023 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01-01-1995 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | - |
Opleiding van Obi Greenman
| Stanford University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CERUS CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
